CAJ | 학술논문

目的：探讨应用替莫唑胺辅助治疗恶性胶质瘤患者的临床效果。方法选取2011年6月至2013年7月经病理学确诊为恶性胶质瘤患者72例为研究对象，采取数字标记法随机分成对照组和观察组，各36例。两组患者均给予常规治疗，并依据体表面积分别给予环己亚硝脲和替莫唑胺辅助化学治疗，定期随访并行强化核磁共振成像(MRI)或电子计算机 X 射线断层扫描技术(CT)检查。对两组患者生活质量、未进展存活率进行调查，并对比两组患者实体瘤临床疗效及不良事件发生率。结果观察组生活质量改善情况明显优于对照组，实体瘤完全缓解率及未进展存活率均明显高于对照组（ P ＜0.05）；不良反应中，除脱发和免疫力下降二者无差别外，观察组疲惫、便秘、头痛眩晕、呼吸短促、贫血、发热等症状均明显少于对照组（ P ＜0.05）。结论替莫唑胺辅助治疗恶性胶质瘤能有效抑制肿瘤生长，延长肿瘤未进展存活期，改善生活质量，且药物毒副作用轻，可作为临床辅助治疗的首选药物。
목적：탐토응용체막서알보조치료악성효질류환자적림상효과。방법선취2011년6월지2013년7월경병이학학진위악성효질류환자72례위연구대상，채취수자표기법수궤분성대조조화관찰조，각36례。량조환자균급여상규치료，병의거체표면적분별급여배기아초뇨화체막서알보조화학치료，정기수방병행강화핵자공진성상(MRI)혹전자계산궤 X 사선단층소묘기술(CT)검사。대량조환자생활질량、미진전존활솔진행조사，병대비량조환자실체류림상료효급불량사건발생솔。결과관찰조생활질량개선정황명현우우대조조，실체류완전완해솔급미진전존활솔균명현고우대조조（ P ＜0.05）；불량반응중，제탈발화면역력하강이자무차별외，관찰조피비、편비、두통현훈、호흡단촉、빈혈、발열등증상균명현소우대조조（ P ＜0.05）。결론체막서알보조치료악성효질류능유효억제종류생장，연장종류미진전존활기，개선생활질량，차약물독부작용경，가작위림상보조치료적수선약물。
Objective To investigate the clinical effect of the temozolomide chemotherapy in the adjuvant treatment of malignant glioma. Methods 72 cases of pathologically diagnosed malignant glioma in our hospital from june 2011 to july 2013 were selected as the research subjects and randomly divided into the control group and observation group by adopting the numeric symbol method,36 cases in each group. The two groups were given the conventional therapy. In addition,the adjuvant chemotherapy of lomustine and temo-zolomide was respectively given according to the body surface area. The regular follow up was carried out and the reinforcement MRI and CT examinations were conducted. The quality of life,survival rate without progress were investigated in the two groups. The clinical effects of the solid tumor and the occurrence rate of adverse events were compared between the two groups. Results The improvement of life quality in the observation group was obviously superior to that in the control group( P < 0. 05);the complete remission rate of solid tumor and the survival rate without progress were significantly higher than those in the control group;in the adverse reactions,ex-cept no differences in alopecia and immunity decrease,the symptoms of fatigue,constipation,headache,vertigo,shortness of breath,anemia and fever in the observation group were significantly less than those in the control group with statistically significant differences(P < 0. 05). Conclusion The temozolomide chemotherapy for the adjuvant treatment of malignant glioma can effectively inhibit the tumor growth,ex-tend the survival period without tumor progress,improve the patient' s life quality with mild toxic and side drug effect,and can be used as the first - choice drug for the adjuvant treatment of malignant glioma.